
    
      1.400 patients with advanced breast cancer should be definitively diagnosis based on
      histopathology, according to the 7th American Joint Committee on Cancer(AJCC) Cancer Staging
      Manual.

      2.All patients will be randomly divided into group A（DC-CIK immunotherapy combined with
      capecitabine ) or group B（capecitabine monotherapy).

      3.Patients in group A will receive 4 cycles of DC-CIK treatment (every 1 year) and
      capecitabine(continuous).Patients in group B will receive only capecitabine
      monotherapy(continuous) .

      4.The response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST)
      guidelines.
    
  